Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 23/7/2018
SIETES contiene 92430 citas

 
 
 1 a 20 de 272 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Joseph A. FDA approves country’s first medicine made from marijuana. STAT Daily Recap 2018:2. [Ref.ID 102664]
2.Enlace a cita original Cita con resumen
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]
3. Cita con resumen
Gorelick DA. The effects of cannabis among adults with chronic pain. Ann Intern Med 2018;168:525. [Ref.ID 102602]
4.Enlace a cita original Cita con resumen
Baket T, Datta P, Rewers-Felkins K, Thompson H, Kallem RR, Hale TW. Transfer of inhaled cannabis into human breast milk. Obstet Gynecol 2018;131:783-8. [Ref.ID 102575]
5.Enlace a cita original Cita con resumen
Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018:6 de marzo. [Ref.ID 102555]
6. Cita con resumen
Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]
8. Cita con resumen
9. Cita con resumen
Anónimo. Outbreak Alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention 2018:5 de abril. [Ref.ID 102503]
11.Tiene citas relacionadas Cita con resumen
Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]
12.Tiene citas relacionadas Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]
13.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
15. Cita con resumen
O'Neil ME, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, Zakher B, Elven C, Motu'apuaka M, Paynter R, Kansagara D. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med 2017;167:332-40. [Ref.ID 102023]
16. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
17.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]
18.Tiene citas relacionadas Cita con resumen
Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699. [Ref.ID 102018]
19. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
20. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
Seleccionar todas
 
 1 a 20 de 272 siguiente >>